EUVIMEDEUVIMED entdecken
Crossref

Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies

Signe Benzon Larsen iD, Frida E Lundberg iD, Søren Friis, Helgi Birgisson, Therese M-L Andersson iD, Gerda Engholm iD, Paul C Lambert iD, Klaus Brasso iD, David Pettersson, Elínborg Ólafsdóttir, Tom Børge Johannesen, Simon M Kønig und 2 weitere

International Journal of Epidemiology · 2025

DOI: 10.1093/ije/dyaf082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Epidemiology, 2025. Verfasst von Signe Benzon Larsen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Kirsten and Freddy Johansen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer survival varies across Nordic countries, potentially reflecting variation in stage distribution at diagnosis. To highlight the variation in the diagnostic intensity of prostate cancer, we outlined the differences in stage distributions at diagnosis across these countries. Specifically, we evaluated whether the variation in cancer survival could be attributed to differences in stage at diagnosis.

Methods

In this population-based cohort study, we identified 243 893 men diagnosed with prostate cancer from 2004 to 2016 in Denmark, Iceland, Norway, and Sweden. Country-specific stage distributions at diagnosis were obtained from individual cancer registry records provided by the NORDCAN collaboration. Relative survival and 95% confidence intervals (CIs) were estimated by using the Pohar Perme estimator. Stage-standardized relative survival was estimated by applying pre-weighting based on the stage distribution of the entire Nordic cohort.

Results

The stage distribution of prostate cancer varied between the Nordic countries, with the highest proportion of early-stage (0–I) cases in Sweden and the highest proportion of advanced-stage (IV) cases in Denmark. When adjusting for differences in stage distribution (i.e. stage standardization), the 5-year relative survival improved in Denmark and Norway within the study period (2004–17), increasing from 83.9% (95% CI, 83.2–84.6) and 91.4% (95% CI, 90.8–92.0) to 87.3 (95% CI, 86.5–88.2) and 93.4% (95% CI, 92.8–94.1). Conversely, the 5-year relative survival declined in Sweden from 90.6% (95% CI, 90.3–91.0) to 88.5% (95% CI, 88.0–89.1).

Conclusion

The distinct differences in stage distributions between the Nordic countries substantially contributed to the variation in prostate cancer survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleAgedMiddle AgedScandinavian and Nordic CountriesNeoplasm StagingRegistriesAged, 80 and overCohort StudiesSurvival AnalysisNorwayIcelandSwedenAdult

Stichwörter der Autor:innen

Nordic countriesincidencemortalityneoplasm stagingprostate neoplasmssurvival

Autor:innen und Institutionen

  • Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Cancer Survivorship, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Cancer Epidemiology and Surveillance, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.

ORCID-Profile: Signe Benzon Larsen, Frida E Lundberg, Therese M-L Andersson, Gerda Engholm, Paul C Lambert, Klaus Brasso, Anna L V Johansson, Lina Steinrud Mørch

Förderung

  • Kirsten and Freddy Johansen Foundation

Zitieren

APA

Larsen, S. B., Lundberg, F. E., Friis, S., Birgisson, H., Andersson, T. M., Engholm, G., Lambert, P. C., Brasso, K., Pettersson, D., Ólafsdóttir, E., Johannesen, T. B., Kønig, S. M., Johansson, A. L. V., & Mørch, L. S. (2025). Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyaf082

Vancouver

Larsen SB, Lundberg FE, Friis S, Birgisson H, Andersson TM, Engholm G, et al. Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies. International Journal of Epidemiology. 2025. doi:10.1093/ije/dyaf082

BibTeX
@article{Larsen2025,
  author = {Larsen, Signe Benzon and Lundberg, Frida E and Friis, Søren and Birgisson, Helgi and Andersson, Therese M-L and Engholm, Gerda and Lambert, Paul C and Brasso, Klaus and Pettersson, David and Ólafsdóttir, Elínborg and Johannesen, Tom Børge and Kønig, Simon M and Johansson, Anna L V and Mørch, Lina Steinrud},
  title = {Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies},
  journal = {International Journal of Epidemiology},
  year = {2025},
  doi = {10.1093/ije/dyaf082}
}
Kostenlos starten →